---
title: "NEWAY released its performance for the first three quarters, with a net profit attributable to the parent company of 1.114 billion yuan, a year-on-year increase of 34.54%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262637580.md"
description: "According to the Zhitong Finance APP, NEWAY disclosed its third-quarter report for 2025. The company achieved revenue of 5.603 billion yuan in the first three quarters, a year-on-year increase of 25.76%; net profit attributable to shareholders was 1.114 billion yuan, a year-on-year increase of 34.54%; net profit excluding non-recurring items was 1.089 billion yuan, a year-on-year increase of 33.33%; basic earnings per share were 1.44 yuan"
datetime: "2025-10-24T12:57:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262637580.md)
  - [en](https://longbridge.com/en/news/262637580.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262637580.md)
---

# NEWAY released its performance for the first three quarters, with a net profit attributable to the parent company of 1.114 billion yuan, a year-on-year increase of 34.54%

According to the Zhitong Finance APP, NEWAY (603699.SH) disclosed its third-quarter report for 2025. The company achieved a revenue of 5.603 billion yuan in the first three quarters, a year-on-year increase of 25.76%; the net profit attributable to shareholders was 1.114 billion yuan, a year-on-year increase of 34.54%; the net profit excluding non-recurring items was 1.089 billion yuan, a year-on-year increase of 33.33%; and the basic earnings per share were 1.44 yuan

### Related Stocks

- [603699.CN](https://longbridge.com/en/quote/603699.CN.md)

## Related News & Research

- [Coffee Prices Rebound on Technical Short-Covering](https://longbridge.com/en/news/286941721.md)
- [Investors Can Find Comfort In Polaris Media's (OB:POL) Earnings Quality](https://longbridge.com/en/news/287004804.md)
- [Oncoinvent grants board chair 1,708 share options, priced at NOK 46.52](https://longbridge.com/en/news/287107218.md)
- [BYD is struggling to meet demand for new fast-charging EVs as orders reach 100K, 60K](https://longbridge.com/en/news/287109883.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)